# US 2015/0174148 A1 · Use of nicotinamide riboside to treat hearing loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174148 A1
- Document ID: US20150174148A1
- Status: Published application
- Kind: A1
- Application number: 14/414,924
- Filed: 2013-07-15
- Published: 2015-06-25
- Earliest claimed: 2013-07-15
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: Kevin Brown; Anthony Sauve; Samie Jaffrey
- Web page: https://patentgrep.com/patent/US20150174148A1

## CPC

- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5058: {Neurological cells}
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.

## Claims

### Claim 1

A method of preventing, mitigating, or treating hearing loss in a mammal in need thereof, comprising administering to the mammal an effective amount of an agent that increases intracellular NAD+ in the mammal, thereby preventing or treating hearing loss in the mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is nicotinamide riboside.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hearing loss is due to noise exposure.

### Claim 4 (depends on 3)

The method of claim 3, wherein the agent is administered to the mammal before noise exposure.

### Claim 5 (depends on 3)

The method of claim 3, wherein the agent is administered to the mammal during noise exposure.

### Claim 6 (depends on 3)

The method of claim 3, wherein the agent is administered to the mammal after noise exposure.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hearing loss is caused by drug toxicity.

### Claim 8 (depends on 7)

The method of claim 7, wherein the drug toxicity results from treatment of the mammal with gentamicin or cisplatin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the hearing loss is associated with Meniere's disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent increases intracellular NAD+ in one or more cells selected from the group consisting of spiral ganglia nerve cells, inner and outer hair cells, supporting cells, and Schwann cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the agent suppresses oxidative damage in the cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the agent activates SIRT3.

### Claim 13 (depends on 1)

The method of claim 1, wherein the treating results in prevention of hearing loss.

### Claim 14 (depends on 1)

The method of claim 1, wherein the treating results in mitigation of hearing loss

### Claim 15 (depends on 1)

The method of claim 1, wherein the agent is administered orally, by injection, or by intratympanic injection into the middle ear space.

### Claim 16 (depends on 1)

The method of claim 1, wherein the mammal is a human or a dog.

### Claim 17

A method of determining if an agent acts as a hearing protective agent, comprising (a) providing a mammal, (b) administering the agent to the mammal, (c) exposing the mammal to noise, and (d) determining the level of NAD+ in hearing-related cells of the mammal, thereby determining if the agent acts as a neuroprotective agent based on the level of NAD+ in hearing-related cells of the mammal.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17, wherein an increase in the level of intracellular NAD+ in hearing related cells of the mammal indicates that the compound acts as a hearing protective agent.
